The present disclosure discloses use of a fused polypeptide with multifunctional activities. In the fused polypeptide with multifunctional activities, the polypeptide contains the following domains: Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys; and Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp; or a sequence of any amino acid mutated in the foregoing domains. The fused polypeptide can be used for treating various fibrosis diseases and symptoms, including pulmonary fibrosis, hepatic fibrosis, skin fibrosis, renal fibrosis, myocardial fibrosis, and lung tissue lesions.

The present application discloses a membrane-type metalloprotease inhibitory protein T1.sup.PrαTACE and use thereof, which can be used for preparing drugs targeting MT1-MMP or TACE endonuclease. The present application discloses an antitumor pharmaceutical composition, comprising BHK-21 cells and an artificial basal membrane which expresses T1.sup.PrαTACE protein.

Disclosed herein is a method of “reprogramming” highly motile cells found in tumors, such as these highly motile GSC and/or MDSC clones, into “auto-destructive” cell “missiles” (referred to herein as therapeutic stealth cells) that can seek and destroy new foci of recurrence within the body, such as the brain. Cells with enhanced motility can be sorted out from heterogeneous populations and then be rendered “auto-destructive” by deterministic delivery of an anti-cancer agent, such as an oncolytic virus plasmid cocktail.

The present invention relates to antibodies or antigen binding fragments thereof that binds to human “TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.

The present invention relates to a novel MMP-8 activation product such as a MMP-8 middle-part activation product. The invention also relates to detecting such a MMP-8 activation product or activated MMP-8 fragments in a biological sample derived from a subject and to the use thereof for diagnosing diseases which relate to abnormal or elevated levels of activated MMP-8.

There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.

In alternative embodiments, provided are compositions, including pharmaceutical compositions and formulations, products of manufacture and kits, and methods, for: enhancing or accelerating liver regeneration, optionally enhancing or accelerating liver regeneration after tissue injury or liver resection; enhancing or accelerating tissue repair, optionally enhancing or accelerating tissue repair after a trauma, an injury or an infection, wherein optionally the injury is an ischemia-reperfusion injury comprising: administering to an individual in need thereof, a compound or composition capable of inhibiting or decreasing the expression or activity of a matrix metalloproteinase (MMP) in a tissue-specific or tissue-selective manner, in in an end organ specific manner, or administering to the organ, for example, a liver, of an individual in need thereof a compound or composition capable of inhibiting or decreasing the expression or activity of a matrix metallo-proteinase.

Described are methods and compositions that provide for generating synthetic or recombinant proline rich peptides. In some aspects, p1978 compositions are used to inhibit breast cancer cell growth and thus provided is a method for treating and preventing breast cancer cell growth in a mammal.

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications related to aging-related cognitive impairment.